Major Biotech Announcements Moving the Market

HENDERSON, NV / ACCESSWIRE / October 10, 2018 / The biotech market is moved by events and announcements. There are a few major events currently impacting the companies highlighted below.

Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers, just announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.

The FDA granted Orphan Drug Designation status to PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.

The Company's lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries - Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.

Last month, the company's CEO presented at the prestigious 25th Annual NewsMakers in the Biotech Industry Conference. The company has demonstrated using both in vitro (cell line) and in vivo (animal) data that PRP effectively suppresses cancer stem cells by suppressing key genes, which are critical to controlling their population and reducing the risk of tumor recurrence, clinically.

They also discovered a key gene target for drug developers, Rac1B, which increased as a result of PRP treatment. This gene suppresses cellular motility and proliferation of CSCs by ultimately inhibiting TGF-β, a known growth factor responsible for tumorigenesis and metastasis.

PPCB's CEO James Nathanielsz said "We remain excited by these important discoveries, as suppressing the CSCs population whilst avoiding potential unwanted side effects towards normal stem cells means we have a targeted therapy that can control the spread of cancer. Metastasis, or spreading cancer, remains the main cause of patient death from cancer."

The company is also very close to its first-in-human studies. PPCB has some very exciting events on the horizon. Of all the companies we've highlighted below, PPCB seems to be the most prime for a massive run.

A few companies to watch include: Propanc Biopharma, Inc. (PPCB), Novavax, Inc. (NVAX), Dynavax Technologies Corp. (DVAX), Arrowhead Pharmaceuticals, Inc. (ARWR), and vTv Therapeutics, Inc. (VTVT).

Propanc Biopharma, Inc. (PPCB)

Market Cap: $15.49M Share Price: $0.092

Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, just announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.

The Company's lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries - Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.

Novavax, Inc. (NVAX)

Market Cap: $791.96M Share Price: $2.07

In a recent conference call NVAX stated ~3.9 million babies are born annually in the United States. About 70% of them are afflicted with RSV (respiratory syncytial virus) before the age of one year. With the high incidence level of RSV, Novavax expects the peak revenue opportunity for its ResVax maternal immunization vaccine program to be ~$750 million in the United States. However, it has only considered babies born full term for its US market opportunity estimate.

Dynavax Technologies Corp. (DVAX)

Market Cap: $701.92M Share Price: $11.21

Dynavax Technologies Corporation announced that data will be presented from its ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada). Data will be presented in three individual sessions with data for advanced melanoma patients who are naïve to anti-PD-1 therapy being presented as a late-breaking abstract poster discussion, at the European Society for Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018 in Munich Germany.

Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap: $1.22B Share Price: $13.89

Arrowhead Pharmaceuticals Inc (ARWR) recently announced Johnson & Johnson (JNJ) would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.

Under the deal, J&J's Janssen Pharmaceuticals unit will obtain a worldwide licence for Arrowhead's ARO-HBV drug and an option to collaborate on up to three new RNA interference (RNAi) drugs, which use gene-silencing technology.

vTv Therapeutics, Inc. (VTVT)

Market Cap: $143.33M Share Price: $3.70

VTVT recently reported its second quarter results. The company reported loss of $0.29 per share for the quarter, which trailed behind the consensus estimates of loss per share of $0.25 by $0.04. vTv Therapeutics reported revenue of $2.47 million, while analysts had expected revenue of $2.46 million. It was revealed at the end of last month that major shareholder Ronald O. Perelman had acquired 1,879,699 shares of vTv Therapeutics stock in a transaction on Thursday, September 6th. The company discovers, develops, and sells orally administered small molecule drug candidates worldwide and has a drug candidate called azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase III clinical trials for the treatment of Alzheimer's disease.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and ninety thousand four hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB. PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communications, LLC. and the hiring party Regal Consulting, LLC. may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Currently Regal Consulting has converted debt into shares and currently owns 6,139,176 shares of PPCB which it plans to sell at anytime without notice.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communications, LLC

View source version on accesswire.com:
https://www.accesswire.com/513819/Major-Biotech-Announcements-Moving-the-Market



View source version on accesswire.com:
https://www.accesswire.com/513819/Major-Biotech-Announcements-Moving-the-Market